NSW Big Ideas Oncology Seminar Series

Hosted by UNSW and USYD, the purpose of this seminary program is to bring national and international thought leaders to share in groundbreaking/blue sky ideas and discoveries, while fostering a collaborative cross-institutional environment that encourages the exchange of knowledge.


Inaugural meeting – Join us for a special seminar on Prostate Cancer from two world-leading international cancer physician-scientists.

LOCATION: University of Sydney, Gunn Building HR Carne Lecture Theatre

DATE: 8 May 2024

TIME: 3:00 - 5:00pm; Join us for after seminar drinks.

Virtual option: CLICK HERE TO JOIN Meeting ID: 938 382 6375; Password: 509617



Professor Robert Bristow, MD

Director, Manchester Cancer Research Centre; Director, CRUK Manchester Centre and Cancer Domain Lead, University of Manchester, UK.

Synergies Between Genomics and the Tumour Microenvironment in Driving Aggressive Prostate Cancer

Professor Bristow joined the University of Manchester as Director of the Manchester Cancer Research Centre (MCRC) in August 2017 with a remit to developing a new cancer strategy for Manchester with a cancer team science approach. The MCRC is a unique partnership between Cancer Research UK, The University of Manchester and the Christie NHS Foundation Trust. A translational oncogenomicist, his primary research interests are in tumour hypoxia, DNA damage signalling and repair in tumours, and the genomics of prostate cancer progression and cancer treatment response. He is particularly interested in novel clinical trials that intensify cancer therapy to prostate cancer patients whose tumours harbour aggressive genetic changes and hypoxic sub-regions.

Professor Massimo (Max) Loda, MD

The David D. Thompson Professor and Chairman of Pathology and Laboratory Medicine at Weill Cornell Medicine and the Newton-Abraham Visiting Professor at Oxford University.

Lipids in Prostate Cancer Pathobiology: Friends and Foes

Professor Loda is an internationally renowned molecular pathologist. He is chair of the Department of Pathology and Laboratory Medicine at Weill Cornell Medicine and pathologist-in-chief at NewYork-Presbyterian/Weill Cornell Medical Center. Previously he was at Dana-Farber Cancer Institute in Boston, as chair of the Department of Oncologic Pathology. He is also a professor of pathology at Harvard Medical School (Emeritus). While being a pioneer in the development of molecular pathology, his research has largely focused on prostate cancer metabolism and the role of the microenvironment in altering the course of the disease. Most notably, the identification of potential vulnerabilities in the metabolic reprogramming of lipid synthesis in these tumours has led to clinical trials with inhibitors of the rate limiting Fatty Acid Synthase enzyme.







